Jens Witsch

Jens Witsch

Auto-generated profile, based on publicly available information

Jens Witsch

University of Pennsylvania

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMercy H. Mazurek
Mercy H. Mazurek
BCBradley A. Cahn
Bradley A. Cahn
MYMatthew M. Yuen
Matthew M. Yuen
APAnjali M. Prabhat
Anjali M. Prabhat
ICIsha R. Chavva
Isha R. Chavva
KSKevin N Sheth
Kevin N Sheth
Radiological examination of the brain is a critical determinant of stroke care pathways. Accessible neuroimaging is essential to detect the presence of intracerebral hemorrhage (ICH). Conventional magnetic resonance imaging (MRI) operates at high magnetic field strength (1.5–3 T), which requires an access-controlled environment, rendering MRI often inaccessible. We demonstrate the use of a low-field MRI (0.064 T) for ICH evaluation. Patients were imaged using conventional neuroimaging (non-contrast computerized tomography (CT) or 1.5/3 T MRI) and portable MRI (pMRI) at Yale New Haven Hospital from July 2018 to November 2020. Two board-certified neuroradiologists evaluated a total of 144 pMRI examinations (56 ICH, 48 acute ischemic stroke, 40 healthy controls) and one ICH imaging core lab researcher reviewed the cases of disagreement. Raters correctly detected ICH in 45 of 56 cases (80.4% sensitivity, 95%CI: [0.68–0.90]). Blood-negative cases were correctly identified in 85 of 88 cases (96.6% specificity, 95%CI: [0.90–0.99]). Manually segmented hematoma volumes and ABC/2 estimated volumes on pMRI correlate with conventional imaging volumes (ICC = 0.955, p = 1.69e-30 and ICC = 0.875, p = 1.66e-8, respectively). Hematoma volumes measured on pMRI correlate with NIH stroke scale (NIHSS) and clinical outcome (mRS) at discharge for manual and ABC/2 volumes. Low-field pMRI may be useful in bringing advanced MRI technology to resource-limited settings.

1 March 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
JWJens Witsch
Jens Witsch
HFHans-Peter Frey
Hans-Peter Frey
JSJ. Michael Schmidt
J. Michael Schmidt
AVAngela Velazquez
Angela Velazquez
CFCristina M. Falo
Cristina M. Falo
JCJan Claassen
Jan Claassen
With the increasing use of continuous electroencephalography (EEG) in neurologic and nonneurologic intensive care units (ICUs), EEG phenomena of unclear significance are detected more frequently.1-4 Among these phenomena, periodic discharges (PDs) are most common.5 The prevalence of PDs ranges in medical and surgical ICU cohorts from 17% to 29% of comatose patients, even after exclusion of patients with neurologic abnormalities.6,7 In neurologic ICUs with more liberal use of continuous EEG, prevalence ranges from 17% to as many as 40% of patients.8-10

30 April 2016 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JWJens Witsch
Jens Witsch
HFHans‐Peter Frey
Hans‐Peter Frey
SPSweta Patel
Sweta Patel
SPSoojin Park
Soojin Park
SLShouri Lahiri
Shouri Lahiri
JCJan Claassen
Jan Claassen

1 January 2017 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
SLSebastian Luger
Sebastian Luger
JWJens Witsch
Jens Witsch
ADAndreas Dietz
Andreas Dietz
GHGerhard F Hamann
Gerhard F Hamann
JMJens Minnerup
Jens Minnerup
CFChristian Foerch
Christian Foerch
BACKGROUND: Recent studies have suggested that glial fibrillary acidic protein (GFAP) serum concentrations distinguish between intracerebral hemorrhage (ICH) and ischemic stroke (IS) shortly after symptom onset. In this prospective multicenter trial we validated GFAP in an independent patient cohort and assessed the quantitative relationship between GFAP release, bleeding size, and localization. METHODS: We included patients with a persistent neurological deficit (NIH Stroke Scale ≥4) suggestive of stroke within 6 h of symptom onset. Blood samples were drawn at hospital admission. GFAP serum concentrations were measured using an electrochemiluminometric immunoassay. Primary endpoint was the final diagnosis established at hospital discharge (ICH, IS, or stroke mimic). RESULTS: 202 patients were included (45 with ICH, 146 with IS, 11 stroke mimics). GFAP concentrations were significantly higher in ICH than in IS patients [median (interquartile range) 0.16 μg/L (0.04–3.27) vs 0.01 μg/L (0.01–0.01), P <0.001]. A GFAP cutoff of 0.03 μg/L provided a sensitivity of 77.8% and a specificity of 94.2% in distinguishing ICH from IS and stroke mimics [ROC analysis area under the curve 0.872 (95% CI, 0.802–0.942), P <0.001]. GFAP serum concentrations were positively correlated with ICH volume. Lobar ICH volumes were larger and thus associated with higher GFAP concentrations as compared to deep ICH. CONCLUSIONS: Serum GFAP was confirmed to be a biomarker indicating ICH in patients presenting with acute stroke symptoms. Very small ICH may be missed owing to less tissue destruction.

29 July 2016 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JCJan Claassen
Jan Claassen
AVAngela Velazquez
Angela Velazquez
EMEmma Meyers
Emma Meyers
JWJens Witsch
Jens Witsch
MFM. Cristina Falo
M. Cristina Falo
HFHans‐Peter Frey
Hans‐Peter Frey

3 May 2021 in Neurological Research and Practice
Verified
Journal Article
Open access
PDF file
JWJens Witsch
Jens Witsch
BSBob Siegerink
Bob Siegerink
CNChristian H. Nolte
Christian H. Nolte
MSMaximilian Sprügel
Maximilian Sprügel
TSThorsten Steiner
Thorsten Steiner
HHHagen B. Huttner
Hagen B. Huttner
Background: Approximately half of patients with spontaneous intracerebral hemorrhage (ICH) die within 1 year. Prognostication in this context is of great importance, to guide goals of care discussions, clinical decision-making, and risk stratification. However, available prognostic scores are hardly used in clinical practice. The purpose of this review article is to identify existing outcome prediction scores for spontaneous intracerebral hemorrhage (ICH) discuss their shortcomings, and to suggest how to create and validate more useful scores. Main text: Through a literature review this article identifies existing ICH outcome prediction models. Using the Essen-ICH-score as an example, we demonstrate a complete score validation including discrimination, calibration and net benefit calculations. Score performance is illustrated in the Erlangen UKER-ICH-cohort (NCT03183167). We identified 19 prediction scores, half of which used mortality as endpoint, the remainder used disability, typically the dichotomized modified Rankin score assessed at variable time points after the index ICH. Complete score validation by our criteria was only available for the max-ICH score. Our validation of the Essen-ICH-score regarding prediction of unfavorable outcome showed good discrimination (area under the curve 0.87), fair calibration (calibration intercept 1.0, slope 0.84), and an overall net benefit of using the score as a decision tool. We discuss methodological pitfalls of prediction scores, e.g. the withdrawal of care (WOC) bias, physiological predictor variables that are often neglected by authors of clinical scores, and incomplete score validation. Future scores need to integrate new predictor variables, patient-reported outcome measures, and reduce the WOC bias. Validation needs to be standardized and thorough. Lastly, we discuss the integration of current ICH scoring systems in clinical practice with the awareness of their shortcomings. Conclusion: Presently available prognostic scores for ICH do not fulfill essential quality standards. Novel prognostic scores need to be developed to inform the design of research studies and improve clinical care in patients with ICH.